Skip to Content
Merck
CN

Key Documents

View All Documentation

G7048

Proguanil hydrochloride

≥95% (HPLC)

Synonym(s):

Chlorguanide, N1-(4-Chlorophenyl)-N5-isopropylbiguanide

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C11H16ClN5·HCl
CAS Number:
637-32-1
Molecular Weight:
290.19
NACRES:
NA.77
PubChem Substance ID:
329799959
UNSPSC Code:
51101906
EC Number:
211-283-7
MDL number:
MFCD01732193
Assay:
≥95% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥95% (HPLC)

form

solid

storage condition

desiccated

solubility

acetonitrile: water: ~1 mg/mL (60/40)

originator

AstraZeneca

storage temp.

2-8°C

SMILES string

Cl.CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1

InChI

1S/C11H16ClN5.ClH/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9;/h3-7H,1-2H3,(H5,13,14,15,16,17);1H

InChI key

SARMGXPVOFNNNG-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Proguanil (chlorguanide) may be used in anti-parasitic protozoan drug development to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an antimalarial drug.

Biochem/physiol Actions

Chlorguanide (proguanil) is combined with atovaquone for malaria prophylaxis. The two compounds act synergistically to inhibit the plasmodial dihydrofolate reductase (DHFR) and interrupt the electron transport chain. Mutations in DHFR account for the development of resistant strains.
Proguanil hydrochloride is antimalarial. Dihydrofolate reductase inhibitor

Features and Benefits

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000148815
050M4719V
0000148815
050M4719V
0000053138

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S Looareesuwan et al.
The American journal of tropical medicine and hygiene, 60(4), 533-541 (1999-05-29)
The continuing spread of drug-resistant malaria emphasizes the need for new antimalarial drugs. Atovaquone is a broad-spectrum antiprotozoal drug with a novel mechanism of action, via inhibition of parasite mitochondrial electron transport, and a favorable safety profile. Early studies with
Sarah Donegan et al.
Statistics in medicine, 31(29), 3840-3857 (2012-07-13)
Mixed treatment comparison (MTC) meta-analysis allows several treatments to be compared in a single analysis while utilising direct and indirect evidence. Treatment by covariate interactions can be included in MTC models to explore how the covariate modifies the treatment effects.
Patricia Schlagenhauf et al.
Expert review of anti-infective therapy, 10(5), 537-546 (2012-06-19)
The concept of 'standby emergency treatment' (SBET) describes the strategy where travelers carry an emergency malaria treatment for self-administration when no medical attention is available or for use under medical supervision after a confirmed malaria diagnosis, and raises many issues
Olivier Bouchaud et al.
Malaria journal, 11, 212-212 (2012-06-23)
Malaria continues to be amongst the most frequent infectious diseases imported to Europe. Whilst European treatment guidelines are based on data from studies carried out in endemic areas, there is a paucity of original prospective treatment data. The objective was
Allan Pamba et al.
Blood, 120(20), 4123-4133 (2012-09-21)
Drug-induced acute hemolytic anemia led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In 2 clinical trials of antimalarial preparations containing dapsone (4,4'-diaminodiphenylsulfone; 2.5 mg/kg once daily for 3 days), 95 G6PD-deficient hemizygous
View All Related Papers

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Global Trade Item Number

SKUGTIN
G7048-50MG04061833642351
G7048-10MG04061833024195

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service